Download the ESMO 2012 Abstract Book - Oxford Journals

More documents

Recommendations

Info

Annals of Oncology multiple locations. As 1 st line therapy, 24% had cytokine or immunotherapy based therapies, 52% sunitinib and 17% sorafenib. The duration of 1 st line therapy was 7.0 months in median for all patients (including cytokines) and 7.8 and 13.7 months for those treated with sunitinib or sorafenib, respectively. 50 patients achieved a second line therapy prior to everolimus, 22 patients were treated with sorafenib and 26 patients with sunitinib dependent on the 1 st line therapy. Most patients treated with everolimus in 2 nd or 3 rd line therapy had an ECOG of 1 (49.4%) followed by ECOG 0 (39.5%) and ECOG 2 (9.9%). The median duration of treatment with everolimus was 4.5 months (0.6–22.5), 36% of the patients were more than 6 months on treatment with everolimus. Best response was CR in 2.5%, PR in 12% and SD in 47% of the patients (CBR 61%). Reasons for discontinuation were PD (72%), intolerance (16%), patients request (6%) and others (6%). 77/81 patients (95%) received a further therapy after discontinuation of everolimus. The agents administered beyond everolimus were sunitinib (29%), sorafenib (29%) and 36% received other therapies as temsirolimus, pazopanib or dovitinib. Best reported responses have been CR (1%), PR (9%), SD (48%) of the reported patients. 27 patients received an additional sequence of therapy (4 th to 5 th line). In summary, these data confirm the results of the RECORD-1 trial in clinical practice and demonstrate a clinical benefit of therapies beyond everolimus. 58% of the patients were still alive at time of evaluation. Disclosure: L. Bergmann: The retrospective analysis was supported by a grant of Novartis Pharma. The presenter has been an advisor for Novartis Pharma. V. Grünwald: Advisory board Novartis. S. Weikert: Advisory board Novartis. T.C. Gauler: Advisary board Novartis. All other authors have declared no conflicts of interest. 876 EFFICACY AND SAFETY OF SEQUENTIAL USAGE OF EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) PREVIOUSLY TREATED WITH BEVACIZUMAB +/- INTERFERON (INF) THERAPY. RESULTS FROM THE EUROPEAN AVATOR RETROSPECTIVE STUDY A. Vuillemin 1 , C. Theodore 2 , L. Jacobasch 3 , J. Schmitz 4 , A. Guillot 5 , C. Papandreou 6 , C. Emmanouilides 7 , K. Slimane 8 , M. Ktiouet 8 , T. Nguyen 1 1 Medical Oncology, Hôpital Jean Minjoz, Besançon, FRANCE, 2 Medical Oncology, HÔPITAL FOCH, Suresnes, FRANCE, 3 Hematology/Oncology, Private Practice for Hematology/Oncology, Dresden, GERMANY, 4 Hematology/ Oncology, Fachklinik Lindenberg/Ried, Lindenberg, GERMANY, 5 Medical Oncology, Institut de Cancérologie de la Loire, Saint Priest en Jarez Cedex, FRANCE, 6 Department of Medical Oncology, University Hospital of Larissa, Larissa, GREECE, 7 Oncology, Iatriko Diavalkaniko Thessalonikis, Thessaloniki, GREECE, 8 Oncology, Novartis Pharmaceuticals, Rueil-Malmaison, FRANCE Background: EVE (Afinitor®) has demonstrated activity in the treatment of mRCC after failure of VEGF-targeted tyrosine kinase inhibitors. However, to this date, there is no published data evaluating its activity/safety after failure of first line BEV-based therapy. Methods: Our non-interventional multicenter international study reports retrospective data on EVE in routine use. Eligible patients had mRCC; were given EVE after 1 prior first-line systemic therapy with BEV +/- INF. The data were provided by each center and centralised. The pts were evaluated for differences in baseline characteristics and prognostic factors (PFs) validated in mRCC. Results: Here are the results from an interim analysis: 20 sites included 43 pts between October 2011 and February 2012. Baseline patient characteristics included median age of 69 [38–90] years old; 64.3% male; 97.5% with prior nephrectomy. First-line therapy was BEV + INF in 69% of patients, only BEV for 31%. Prognostic groups at the time of EVE initiation according to Heng (1) and to MSKCC (2) were respectively: (1): good 25%, intermediate 59.4% and poor prognosis 15.6% and (2) good 28.1%, intermediate 56.3% and poor 15.6%. Median duration of treatment with first line therapy was 7.5 months, it was discontinued for disease progression in 61.9 % of pts. Median EVE treatment duration with was 5 [3.0–7.0] months. Median progression free survival (PFS) has not yet been reached as 15 pts are still receiving EVE. Overall response rate was 9.5 % and disease stabilization rate was 50%. At least one adverse event (AE) occurred in 73.8 % of pts with 13 serious AEs. All grade common AEs were consistent with the toxicity profile of EVE with 31% of stomatitis, 16.7% of pneumonitis, 31% of fatigue. Conclusions: This study provided encouraging results for the activity and safety profile of EVE in second line mRCC setting and warrants further investigation after 1 prior first-line therapy with bevacizumab-based regimen. Final results with mature PFS data and median overall survival from initiation of first-line therapy will be available in 2013. Disclosure: A. Vuillemin: Consulting fees : Novartis, Sanofi-Aventis, Ferring Member of Novartis Advisory board Honorarium study NovartisC. Theodore: Research grant from Novartis Consulting fees from Novartis Honorarium study NovartisL. Jacobasch: Honorarium study NovartisA. Guillot: Member of Novartis Advisory board Speaker at Novartis regional meetings Honorarium study NovartisC. Papandreou: Participated to advisory boards for NovartisC. Emmanouilides: Research grants : Novartis, Pfizer, GSKK. Slimane: Novartis employeeM. Ktiouet: Novartis EmployeeT. Nguyen: Honorarium study NovartisAll other authors have declared no conflicts of interest. 877 A REVIEW OF RADIOLOGICAL ASSESSMENT RESPONSE IN METASTATIC RENAL CELL CARCINOMA TREATED WITH ANTIANGIOGENIC THERAPY- ARE WE HITTING THE TARGET? T. Montella 1 , D. Herchenhorn 2 1 INCA, Rio de Janeiro, BRAZIL, 2 Medical Oncology, Brazilian National Cancer Institute, Rio de Janeiro, BRAZIL Background: Targeted therapy has changed the treatment landsacpe of metastatic renal cell carcinoma (RCC) in the last years. However, despite the positive results with antiangiogenic drugs in the treatment of metastatic RCC, the evaluation of response to these therapies remains undefined. This study aimed to review different proposed radiologic methods used for response evaluation with antiangiogenic agents in RCC. Methods: A no systematic literature review using electronic databases PubMed/ MEDLINE, EMBASE, Cochrane Library and LILACS with the terms “renal cell carcinoma”, “response criteria” and “targeted therapy” and its variables. Results: A total of 53 articles were identified, of which 12 were selected and 41 excluded. After evaluation of the references of the 12 selected studies, two new studies were included. The 14 studies were published from August 2009 to October 2011, 11 of them using computed tomography as a method of response evaluation, one with doppler ultrasound and two others with positron emission tomography. A total of 927 patients were studied. The drugs used for analysis in the different studies were sunitinib, sorafenib, cediranibe, bevacizumab and interferon alpha; but sunitinib and sorafenib are variously present in all studies. The retrospective design was the basis for most of the analysis (71%) and endpoints analysed for method comparison were time to disease progression (TTP) or progression-free survival (PFS). All studies had RECIST as the assessment parameters (control). Proposed new methods of radiographic response criteria in this context were present in 11 studies (78%). In 3 studies (21%) only one radiologist reviewed the images, in the other at least 2 radiologists participated in the evaluation. Most studies evaluated a small number of patients and 8 studies (57%) included more than one antiangiogenic drugs in its analysis. Conclusion: Antiangiogenic drugs are considered standard therapy in the treatment of metastatic RCC. Phase III trials are needed to validate the best radiological response criteria in this context, new proposed methods should be incorporated as secondary end-points in future prospective trials. Disclosure: All authors have declared no conflicts of interest. 878 THE ROLE OF NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA – A SINGLE CENTRE ANALYSIS J. Neves 1 , I. Fernandes 2 , J. Ribeiro 2 , D. Macedo 2 , L. Costa 2 1 Faculty of Medicine, University of Lisbon, Lisbon, PORTUGAL, 2 Oncology Division, Santa Maria Hospital (HSM-CHLN), Lisbon, PORTUGAL The approval of new therapeutic options has increased the survival of metastatic renal cell carcinoma (mRCC) patients (pts). These drugs were mostly studied in pts who underwent nephrectomy (Sx) prior to the diagnosis of metastatic disease (MD). Sx is also indicated for pts with MD who are suitable and have good performance status (PS). The aim of this work is to retrospectively analyse the benefit of Sx in the pts with mRCC referred to the Oncology Division at Santa Maria Hospital from 01/ 2006 to 10/2010. Two groups of pts were defined: pts who had Sx and pts who had no Sx. The first group was further divided into pts who had Sx whilst with non-MD (SxNMD) and pts who did it whilst with MD (SxMD). With significance set at p = 0.05 and the aid of IBM® SPSS® Statistics 20, statistical analysis was performed using descriptive statistics and Fisher’s exact test. Overall survival (OS) - time from diagnosis of MD to death - was plotted using the Kaplan–Meier method and compared by log-rank test. The population had 44 pts: 72,7% (n = 32) male, 59,1% (n = 26) under 65 years old, 90,9% (n = 40) with Karnofsky PS (KPS) ≥80 and 59,1% (n = 26) with clear cell carcinoma. Half were diagnosed with non-MD (NMD) (n = 22) and progressed to MD in a mean of 45,9 months (m). Thirty-eight pts (86,4%) did medical therapy, of those 86,8% (n = 33) had favourable or intermediate risk according to the Memorial Sloan Kettering Cancer Center (MSKCC) criteria and 86,8% (n = 33) did target therapy. Thirty pts underwent Sx (68,2%) and 14 didn’t (31,8%). There was no statistical difference between groups regarding gender, age, KPS, histology, MSKCC risk and medical therapy. The median OS was 14 and 27 m respectively for the no Sx group versus the Sx group (p = 0,027). In the pts who had Sx, 21 (70%) were part of the SxNMD group and 9 (30%) of the SxMD group. Except for Fuhrman grade (p = 0,022), there was no statistical difference between groups regarding gender, age, KPS, histology, MSKCC risk and medical therapy. The median OS for SxNMD had not been reached while the median OS for SxMD was 21 m (p = 0,682). In the population studied there was no difference in OS curves between the SxNMD group and the SxMD group. This suggests that Sx has a valuable role in pts diagnosed with MD in addition to medical therapy, namely target therapy. Disclosure: All authors have declared no conflicts of interest. Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds399 | ix289
879 TREATMENT OF PATIENTS WITH METASTATIC KIDNEY CANCER DURING HAEMODIALYSIS WITH MTOR INHIBITORS C. Masini 1 , M. Milella 2 , G. Di Lorenzo 3 , A. Onofri 4 , M. Santoni 4 ,V.Prati 5 , M. Nicodemo 6 , P.F. Conte 1 , R. Sabbatini 1 1 Dept. of Hematology/oncology, Ospedale Policlinico-Modena, Modena, ITALY, 2 Divisione Di Oncologia Medica A, Istituto Nazionale Tumori Regina Elena, Roma, ITALY, 3 Genitourinary Cancer Section and Rare-cancer Center, University Federico II, Napoli, ITALY, 4 Clinica Di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche, Ancona, ITALY, 5 Oncologia Medica A Direzione Universitaria, Fondazione del Piemonte per l’Oncologia, Istituto per la Ricerca e la Cura del Cancro, Torino, ITALY, 6 Divisione Di Oncologia, Ospedale “Sacro Cuore-Don Calabria” Negrar, Verona, ITALY Background: On the basis of a few published data, sunitinib and sorafenib can be administered safely to patients (pts) with metastatic renal cell carcinoma (mRCC) and end-stage renal disease on haemodialysis (HD). Aim of this study was to investigate the safety and efficacy of temsirolimus and everolimus in pts with mRCC on HD. Patients and methods: between September 2007 and February 2012, 13 pts with mRCC undergoing HD were treated with temsirolimus and everolimus in 6 Italian Institutions. We retrospectively reviewed the medical records of these pts to evaluate the doses of mTOR inihibitors administered, the tolerability and the activity of the treatment. Results: Gender: 9 males/4 females; median age: 63 years (range 47–79). All pts were undergoing HD, in 7 cases for bilateral nephrectomy; the time interval between the start of HD and the start of mTOR inhibitors treatment was 37 months. Everolimus was administered at 10 mg daily in 5 pts and at 5 mg in one patient; 7 pts received temsirolimus at 25 mg weekly. Everolimus was administered as second-line treatment in 4 pts, as third and fourth-line in two pts; temsirolimus was given as first-line treatment to 4 pts, as second-line to one patient and as third-line to 2 pts. No unexpected adverse event (AE) and no grade 4 haematological or non-haematological toxicity were reported. The most common grade 1–2 non-haematological treatment-related AEs were fatigue (9/13 pts), dyslipidemia (4/13 pts), oral mucositis in 2/13 pts. A grade 3 dyspnea due to interstitial pneumonia led to treatment discontinuation. The most frequent grade 1–2 haematologic toxicity was anemia (10/13 pts). None of the patients had to change the number of dialysis sessions during mTOR inhibitors treatment. None of the pts experienced an objective response while a disease stabilization was observed in 7 pts. At the time of the analysis, 7 pts had died due to disease progression. The estimated median progression-free survival (PFS) of this cohort of pts was 6.1 months. Conclusions: In this small retrospective series of pts the incidence of AEs was as expected, and a prolonged PFS was observed. The use of temsirolimus and everolimus is not contraindicated in pts with mRCC and severe renal impairment on HD. Disclosure: All authors have declared no conflicts of interest. 880 LIVER TOXICITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH PAZOPANIB THERAPY F.L. Lim 1 , J. Shamash 2 , P. Wilson 2 , T. Powles 3 1 Department of Medical Oncology, St. Bartholomew’s Hospital, London, UNITED KINGDOM, 2 QMUL, Barts Cancer Insititute, London, UNITED KINGDOM, 3 Barts Cancer Institute, St Bartholomew’s Hospital QMUL, London, UNITED KINGDOM Purpose: Pazopanib is a vascular endothelial growth factor receptor, platelet derived growth factor receptor and c-kit tyrosine kinase inhibitor, used in the treatment of metastatic renal cell carcinoma. It is associated with liver toxicity, although timing severity management and consequences of this toxicity is not known. Patients and methods: Sequential patients who were treated with 1 st line pazopanib for their metastatic renal cancer were identified from a prospective data base. Four weekly liver monitoring occurred. Specific protocols for the management of grade 1-4 toxicity were followed. Toxicity was graded based on the clinical toxicity criteria (CTC) grading classification. Patients who developed grade 2 or more toxicity had a structured treatment interruption and dose reduction according to local policy. Results: 44 patients were identified as having received pazopanib treatment between 2009-2012. Fifteen (34%) of whom developed liver toxicity as evidence by a raise in either bilirubin or alkaline transaminase levels (Maximum CTC grade 1 = 4 (27%), 2 = 6 (40%), 3 = 5 (33%), 4= 0 (0%), 5 = 0 (0%). Maximum toxicity occurred a median 60 days after commencing therapy (range 14 – 83 days). Resolution occurred in all but 1 patient (grade 1 or less after stopping the treatment for a median of 3-21 days. All patients restarted pazopanib. Twelve (80%) of these with a dose reduction. Recurrence of raised liver function occurred in 4 (27%) patients (grade 1 = 3 (20%) grade 2 = 1 (7%) rechallanged with pazopainb. One patient died of progression of disease with a concurrent transaminitis (grade 1). The development of a transamitinits was associated with increased progression free survival (HR 0.35 95% CI 0.15 - 0.87 p = 0.024). Conclusion: Liver toxicity in patients treated with pazopanib occurs in 1/3 of patients, usually in the first 12 weeks of therapy. Management is facilitated by blood monitoring, temporary cessation of therapy and dose reductions. Transaminitis may be associated with improved outcomes. Disclosure: All authors have declared no conflicts of interest. Annals of Oncology 881 SEQUENTIAL USE OF TREATMENT OPTIONS IN ADVANCED RENAL-CELL CARCINOMA (RCC): A RETROSPECTIVE ANALYSIS OF 42 PATIENT CASES L. Derosa 1 , L. Galli 2 , A. Fontana 1 , E. Biasco 3 , R. Marconcini 1 , C. Cianci 4 , A. Farnesi 1 , F. Orlandi 1 , A. Falcone 5 1 Polo Oncologico, Azienda Ospedaliero Universitaria S.Chiara, Pisa, ITALY, 2 Azienda Ospedaliero-universitaria Pisana, Istituto Toscano Tumori, Division of Medical Oncology, Pisa, ITALY, 3 Azienda Ospedaliero-universitaria Pisana, Istituto Toscano Tumori, 1Division of Medical Oncology, Pisa, ITALY, 4 Istituto Toscano Tumori, Azienda Ospedaliero-Universitaria Pisana, Pisa, ITALY, 5 Oncologia, Trapianti E Nuove Tecnologie In Medicina, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, Pisa, ITALY The best sequence of targeted therapy options has not been sufficiently defined and also the significance of Cytokine (Cy) in TKI (Sorafenib-So, Sunitinib-Su) and mTOR era. The objective of this study was to describe the clinical activity of sequence options in 2nd line treatment. Methods: Retrospective study of 42 patients receiving TKI or Everolimus (EV) treatment after progression on first-line therapy. Sequence of systemic targeted treatment consisted of an Cy-TKI-sequence (n = 20; Cy-So, n = 12; Cy-Su, n = 8), TKI-TKI-sequence (n=15;Su-So,n=11;So-Su,n=4)oranTKI-EV-sequence(n=7;Su-EV,n=7).We measured response to treatment (RECIST 1.0). Progression free survival (PFS) and overall survival (OS) were determined using the Kaplan-Meier method. Results: Sequence treatment groups did not significantly differ by gender, MSKCC prognostic group, or ECOG PS. Best response to 2nd line therapy included CR (Su: n = 2, sequential therapy after Cy), PR (So: n = 3, after Cy) and SD (EV: n = 5, after TKI; TKI: n = 13; So: n = 5 after Cy, Su: n= 3 after So, n= 5 after Cy). The estimated 2nd line PFS was 5.2 months for EV and 5.86 months for So sequential therapy after Su, 6.56 months for So sequential Cy, 6.7 months for Su sequential therapy after So, 6.54 months for Su sequential Cy. The estimated OS was longer for the group of patients receiving the Cy-TKI-sequence (49.87 months; 95% CI:16–26 for the group Cy-So and 40.36 months; 95% CI:16–26 for the group Cy-Su) and TKI-EV sequence (40.72 months; 95%CI:32–48) than for those receiving the TKI-TKI sequence So-Su (33.36 months, 95%CI:21–62) and Su-So (16.32 months, 95%CI:13–37). However, the TKI-TKI group was characterized by a relatively short first-line PFS (6.12 months of the Su-So group to 12.37 So-Su compared to 12.8 months of the TKI-EV group) which may at least in part explain the observed OS difference. Conclusions: Common sequence treatment options may have comparable efficacy in terms of PFS and response. The observed differences in OS await further confirmation in prospective randomized trials. Disclosure: All authors have declared no conflicts of interest. 882 USING OF LACTOBACTERIN IN COMBINED TREATMENT OF SUPERFICIAL URINARY BLADDER CANCER S. Babakulov 1 , S. Navruzov 2 1 Urology, National Cancer Center of Uzbekistan, Tashkent, UZBEKISTAN, 2 Coloproctology, National Cancer Center of Uzbekistan, Tashkent, UZBEKISTAN Background: to improve combined treatment results of bladder cancer in combination with intra-bladder introduction of Lactobacterine. Materials and methods: During 2010 and 2011 years in National cancer research centre underwent a course of treatment 50 patients with superficial bladder cancer. Those patients divided in two groups. Main group 25 patients and control group 25 accordingly. All patients had morphological confirmed transitional cell carcinoma with histological differentiation G1-G2. Patients before hospitalization had bacteriological study of urine. Bacteriological analysis of urine revealed in 14 (28 %) patients presence of - E. Coli, in 16 (32 %) – S. aureus, in 12 (24%) - Ps. Aeruginosa and in 8 (16%) Klebsiella. After diagnosing of histological structure of the tumor and bladder microflora patients undergone transurethral resection of tumor. Patients in control group after TUR took intravisical chemotherapy with doxorubicin 50 mg once in a week 6 courses. Patients in main group after TUR took intravisical chemotherapy with doxorubicin 50 mg once in a week 6 courses and instillation of collibacterin. Treatment regimen was everyday instillation of probiotic collibacterin 20 mg (5 doses) dissolving in 30 ml of 5% glucose solution per day during 5 days. After the course patients took 3 mg of dried collibacterin per os during the year. Results: It was detected that side effects of intravisical chemotherapy in the form of bladder disorders in control group was revealed almost in every case. Patients of main group only 2 of them had insignificant pain during urination. Study of one year recurrent free survival rate showed that in main group one patient had recurrence of cancer in 310 th day after surgery. In control group 8 (32%) patients had recurrence in the course of year after operation. Conclusions: Using of intravisical probioticotherapy in combined treatment of superficial urinary bladder cancer allows to decrease side effects of chemotherapy and prolong one year recurrent free survival rate with superficial urinary bladder cancer. Disclosure: All authors have declared no conflicts of interest. ix290 | Abstracts Volume 23 | Supplement 9 | September 2012
Page 1 and 2:
Annals of Oncology www.annonc.oxfor
Page 3 and 4:
subscriptions A subscription to Ann
Page 6 and 7:
Annals of Oncology Official Journal
Page 8 and 9:
The European Society for Medical On
Page 10 and 11:
Audit Committee Chair: Fortunato Ci
Page 12 and 13:
Familial cancer Judith Balmaña, Ba
Page 14 and 15:
ESMO 2012 Congress Travel Grants 47
Page 16 and 17:
Exhibitors The following companies
Page 18 and 19:
ESMO Fellowships, 1989-2011 The Eur
Page 20:
Ondrej Gojis, Czech Republic 2008-2
Page 23 and 24:
abstracts hpv biology and implicati
Page 25 and 26:
abstracts the characterization of l
Page 27 and 28:
abstracts description of intra-tumo
Page 29 and 30:
prevent cell death. It is anticipat
Page 31 and 32:
22IN TARGETING THE HOST IN TNBC G.
Page 33 and 34:
abstracts a paradigm shift in early
Page 35 and 36:
abstracts how can medical oncologis
Page 37 and 38:
feasibility), but by how high the c
Page 39 and 40:
abstracts re-inventing the medical
Page 41 and 42:
abstracts emerging diagnostic and t
Page 43 and 44:
abstracts biologically based treatm
Page 45 and 46:
abstracts molecular targets in mali
Page 47 and 48:
abstracts melanoma therapy: from fr
Page 49 and 50:
diagnosis and can also be used for
Page 51 and 52:
analysis at 11 months median follow
Page 53 and 54:
mouse model of Kras mutant NSCLC. I
Page 55 and 56:
abstracts subtyping soft tissue sar
Page 57 and 58:
abstracts key topics in supportive
Page 59 and 60:
ESMO-CSCO Joint Symposium: Building
Page 61 and 62:
ESMO-EANM-ESR Joint Symposium: Imag
Page 63 and 64:
ESMO-ESTRO Joint Symposium: Innovat
Page 65 and 66:
ESMO-MASCC Joint Symposium: Integra
Page 67 and 68:
ESO Society Symposium: Celebrating
Page 69 and 70:
Results: TIMP-1 expression was incr
Page 71 and 72:
will benefit from this targeted the
Page 73 and 74:
cytomegalovirus (CMV). Analysis of
Page 75 and 76:
functional consequences of Endoglin
Page 77 and 78:
elationship between the ROR score,
Page 79 and 80:
183P EPIDERMAL GROWTH FACTOR RECEPT
Page 81 and 82:
Plasma adiponectin level on the pre
Page 83 and 84:
Table: 198P PFS OS Median, mo HR Me
Page 85 and 86:
204P EVALUATION OF PTEN AND PIK3CA
Page 87 and 88:
Material and methods: We searched P
Page 89 and 90:
Results: The median concentration o
Page 91 and 92:
Table: 226P Methods: Pts were rando
Page 93 and 94:
However, additional analysis sugges
Page 95 and 96:
number of biomarkers have been trie
Page 97 and 98:
Table: 248O 249PD PROTEOMIC PREDICT
Page 99 and 100:
Conclusions: BW and serum Ctrough o
Page 101 and 102:
261P BREAST CANCER SUBTYPES AND OUT
Page 103 and 104:
90 mg/m2-cyclophophamide 600 mg/m2
Page 105 and 106:
to 9 weeks after dosing. Trastuzuma
Page 107 and 108:
Patients and methods: We reviewed d
Page 109 and 110:
sector patients. The aim of this st
Page 111 and 112:
Linear Logistic Model with Relaxed
Page 113 and 114:
Results: The median CTC fold change
Page 115 and 116:
312: Table: Chemotherapy uptake wit
Page 117 and 118:
abstracts breast cancer, locally ad
Page 119 and 120:
Results: 8 trials (2092 pts) with 1
Page 121 and 122:
absolute difference of median value
Page 123 and 124:
Novartis, Genentech, and sanofi-ave
Page 125 and 126:
Results: Three RCTs with 1023 patie
Page 127 and 128:
collected from all patients for det
Page 129 and 130:
355P FIRST REPORT OF LONG-TERM RESP
Page 131 and 132:
361P A RETROSPECTIVE ANALYSIS OF PL
Page 133 and 134:
publications and aggregated in a me
Page 135 and 136:
Thus the primary aim to target BCSC
Page 137 and 138:
383 WHY DO WOMEN WITH BREAST CANCER
Page 139 and 140:
Results: We evaluated 76 pts with M
Page 141 and 142:
more than 6 cycles of capecitabine.
Page 143 and 144:
406TiP PHASE II TRIAL OF PRIMARY SY
Page 145 and 146:
abstracts CNS tumors 410O CONDITION
Page 147 and 148:
Conclusions: Our data suggested tha
Page 149 and 150:
Conclusions: As in other cancer typ
Page 151 and 152:
432 GAMMA KNIFE RADIOSURGERY AS A M
Page 153 and 154:
abstracts developmental therapeutic
Page 155 and 156:
1PR), but no responses were seen in
Page 157 and 158:
RO and Cd, as well as PD data for c
Page 159 and 160:
and vulvar Ca), and 11 SDs were obs
Page 161 and 162:
knowing HLA-A status double-blindly
Page 163 and 164:
Acquired-resistance to EGFR inhibit
Page 165 and 166:
474P PHASE 1 STUDY OF THE SELECTIVE
Page 167 and 168:
TST is active in breast and gastric
Page 169 and 170:
Treatment-induced shedding of circu
Page 171 and 172:
Methods: Either co-cultures of peri
Page 173 and 174:
501 PRECLINICAL DATA INVESTIGATING
Page 175 and 176:
509TiP LUX-LUNG 8: A RANDOMIZED, OP
Page 177 and 178:
(P = 0.64). Synchronous BBC was sig
Page 179 and 180:
abstracts gastrointestinal tumors,
Page 181 and 182:
Disclosure: M. Lee: I am an employe
Page 183 and 184:
plus intravenous Bev(7.5mg/kg q 21d
Page 185 and 186:
anti-EGFR treatment. The present st
Page 187 and 188:
patients harboring a T/T genotype t
Page 189 and 190:
551P ADJUVANT CHEMOTHERAPY (AC) USE
Page 191 and 192:
experienced significantly more ≥
Page 193 and 194:
functioning scales. Exploratory ana
Page 195 and 196:
oxaliplatin (100 mg/m 2 )/raltitrex
Page 197 and 198:
572P PANERB STUDY: WHICH CATEGORY O
Page 199 and 200:
Results: 92/114 patients were preop
Page 201 and 202:
585P CHANGES IN THE INTESTINAL ENVI
Page 203 and 204:
592P PHASE II TRIAL OF COMBINED CHE
Page 205 and 206:
minutes. In a previous study, 30-mi
Page 207 and 208:
Patients and methods: Chemotherapy-
Page 209 and 210:
612P ARE PATIENTS WITH RESECTABLE R
Page 211 and 212:
Conclusions: AMPK and ACC activatio
Page 213 and 214:
of surgical monotherapy in patients
Page 215 and 216:
Table: 632 633 AFLIBERCEPT/FOLFIRI
Page 217 and 218:
factors play the determining role i
Page 219 and 220:
Abstract withdrawn in exceptional c
Page 221 and 222:
were respectively 10.6 vs 8.5 vs 3.
Page 223 and 224:
Results: 20 gastrointestinal cancer
Page 225 and 226:
abstracts gastrointestinal tumors,
Page 227 and 228:
Day 8. A second identical course wa
Page 229 and 230:
proven in stage I GC. The aim of th
Page 231 and 232:
Conclusions: Longer OS to FOLFOX wa
Page 233 and 234:
692P PRELIMINARY SAFETY DATA FROM A
Page 235 and 236:
subgroup. Taking into consideration
Page 237 and 238:
Results: Three years of adjuvant im
Page 239 and 240: considered sufficient to give an 80
Page 241 and 242: 721P FIRST-LINE TREATMENT WITH FOLF
Page 243 and 244: after Gem-based therapy. The additi
Page 245 and 246: 735P RADIOGRAPHIC PARAMETERS IN PRE
Page 247 and 248: validate the revised AJCC 7th stagi
Page 249 and 250: Results: Among 862 MM we identified
Page 251 and 252: Results: Frequently reported advers
Page 253 and 254: gastric cancer patients with CNS me
Page 255 and 256: discriminate the prognosis of HCC p
Page 257 and 258: prospective, non-interventional stu
Page 259 and 260: abstracts genitourinary tumors, non
Page 261 and 262: 787O EXTERNAL VALIDATION OF THE ASS
Page 263 and 264: patient preference for P over S, an
Page 265 and 266: 798PD OPEN-LABEL PHASE II TRIAL OF
Page 267 and 268: Hb, PS and LM. Median PFS for patie
Page 269 and 270: may have led to reduced dose and sh
Page 271 and 272: Results: 1,622 patients were identi
Page 273 and 274: RCC) was designed to address an unm
Page 275 and 276: Patients and methods: This is a sin
Page 277 and 278: treatment at week 4, and week 12 by
Page 279 and 280: effective in second or further line
Page 281 and 282: Conclusions: In pts with RCC treate
Page 283 and 284: using Drug inCode ® pharmacogeneti
Page 285 and 286: Table: 857P standard, but is not av
Page 287 and 288: efused HDCT. Of 23 patients, 20 com
Page 289: we identified 49 and 220 patients w
Page 293 and 294: Median overall survival (OS) was 26
Page 295 and 296: abstracts Genitourinary tumors, pro
Page 297 and 298: and week 13 BPI-SF Q3 scores), 28%
Page 299 and 300: Working Group (PCWG)-2 guidelines r
Page 301 and 302: atio HR 0.39; CI 0.18, 0.83, p = 0.
Page 303 and 304: We observed tumor responses and pro
Page 305 and 306: Here we report emerging data from t
Page 307 and 308: 928P LHRH AGONIST-INDUCED SUPPRESSI
Page 309 and 310: Disclosure: S. Oudard: Has acted as
Page 311 and 312: 939P NEOADJUVANT SIPULEUCEL-T IN LO
Page 313 and 314: 945 BONE TURNOVER MARKERS AND POTEN
Page 315 and 316: 952 SEQUENTIAL ANDROGEN DEPRIVATION
Page 317 and 318: managed in a multidisciplinary (MD)
Page 319 and 320: or hypercalcemia at screening; prio
Page 321 and 322: meeting. The prevalence of LGSC is
Page 323 and 324: Table: 975PD Continued AMG 386 + pa
Page 325 and 326: physicians in the U.S. and Europe.
Page 327 and 328: 989P PHASE II STUDY OF COMBINATION
Page 329 and 330: elated with stage, nodal involvemen
Page 331 and 332: 1004P CASE CONTROL STUDY ON TWO DIF
Page 333 and 334: eight patients who had infertility
Page 335 and 336: abstracts head and neck cancer 1016
Page 337 and 338: same CT/RT; Arm B2: 3 cycles of ind
Page 339 and 340: induction chemotherapy in the treat
Page 341 and 342:
patients. We have developed a rando
Page 343 and 344:
evaluated by the screening instrume
Page 345 and 346:
morbidities that radiation would le
Page 347 and 348:
Conclusions: Through adequate selec
Page 349 and 350:
abstracts hematological malignancie
Page 351 and 352:
anthracyclines in vitro. A favorabl
Page 353 and 354:
1076P RITUXIMAB PLUS SUBCUTANEOUS C
Page 355 and 356:
than the standard target of ≥2.5
Page 357 and 358:
Patients: From November 2002 to May
Page 359 and 360:
lymphadenopathy and multiple cutane
Page 361 and 362:
prospective non-interventional stud
Page 363 and 364:
Funding: GSK Biologicals Disclosure
Page 365 and 366:
survival rates of 13-25% (Prieto et
Page 367 and 368:
high response rates and prolonged p
Page 369 and 370:
GlaxoSmithKline, Merck Sharp & Dohm
Page 371 and 372:
advisor for Merck Sharp & Dohme, an
Page 373 and 374:
or cutaneous melanoma. A survival u
Page 375 and 376:
systemic therapy or were intolerant
Page 377 and 378:
abstracts neuroendocrine tumors and
Page 379 and 380:
morbidity, with G3 tumors behaving
Page 381 and 382:
pts. Poorly differentiated endocrin
Page 383 and 384:
Adenocarcinoma was present in 25 pa
Page 385 and 386:
Method: Endobronchial ultrasound gu
Page 387 and 388:
widely used by single agent or plat
Page 389 and 390:
disease after surgery were treated
Page 391 and 392:
stage IIIA NSCLC, EML4-ALK fusion-p
Page 393 and 394:
1200P CONCOMITANT CHEMORADIATION GI
Page 395 and 396:
Patients and methods: The study was
Page 397 and 398:
months (95% CI:13-25). The PFS and
Page 399 and 400:
maintenance therapy had favourable
Page 401 and 402:
abstracts non-small cell lung cance
Page 403 and 404:
Ingelheim, GSK Biologicals (compens
Page 405 and 406:
1234PD RANDOMIZED PHASE III TRIAL O
Page 407 and 408:
GlaxoSmithKline (myself, compensate
Page 409 and 410:
1243P IDENTIFICATION OF MICRORNA (M
Page 411 and 412:
N-arm n=34 P-arm n=32 All n=66 Male
Page 413 and 414:
1255P POPULATION BASED EVALUATION O
Page 415 and 416:
1262P DISTINCT SPREAD OF EGFR MUTAT
Page 417 and 418:
1268P VISUAL DISTURBANCES IN PATIEN
Page 419 and 420:
MERCK SERONO: Advisor, speaker in s
Page 421 and 422:
Conclusions: These data from SAiL a
Page 423 and 424:
NSCLC diagnosis and time of BM diag
Page 425 and 426:
1291P PHASE I/II DOSE-FINDING STUDY
Page 427 and 428:
Network utilization of WBCGF in the
Page 429 and 430:
1303P COST EFFECTIVENESS OF PEMETRE
Page 431 and 432:
Results: The patients’ characteri
Page 433 and 434:
EGFR mut at exons 18, 19, 21, and K
Page 435 and 436:
Methods: EML4-ALK fusion was screen
Page 437 and 438:
Results: The median survival time (
Page 439 and 440:
enefit from sustained EGFR blockade
Page 441 and 442:
epresented by 19 pts (32%) female,
Page 443 and 444:
and at least one prior course of ch
Page 445 and 446:
Methods: NSCLC patients with radiog
Page 447 and 448:
1367TiP LONG-TERM ERLOTINIB THERAPY
Page 449 and 450:
Austria, Czech Republic, Finland, G
Page 451 and 452:
were every 6 weeks (wk) (S1), every
Page 453 and 454:
Advantage enrollees (83% vs. 25%) [
Page 455 and 456:
Results: Based on 10,000 simulation
Page 457 and 458:
cancer tumors 12%, Germ cell tumor
Page 459 and 460:
Material and methods: 50 lung cance
Page 461 and 462:
1414TiP IMPLEMENTATION OF CANCER RE
Page 463 and 464:
abstracts palliative care 1422O EFF
Page 465 and 466:
Method and results: A total of 317
Page 467 and 468:
1436P SURVEY ON MODELS OF INTEGRATI
Page 469 and 470:
care unit (PCU) at the National Can
Page 471 and 472:
Characteristic No. % Total 63 1 st
Page 473 and 474:
hysterectomised-9.10% and cervix ca
Page 475 and 476:
abstracts psycho-oncology 1462PD IN
Page 477 and 478:
events, tumour response, and surviv
Page 479 and 480:
abstracts sarcoma 1477O ADHESION TO
Page 481 and 482:
1481PD A PHASE II STUDY OF DOVITINI
Page 483 and 484:
1488P ORGANISATION OF SARCOMA PATIE
Page 485 and 486:
Patients and methods: From August 2
Page 487 and 488:
chemotherapy respectively. At a med
Page 489 and 490:
of this group Those with relapsed d
Page 491 and 492:
1515 PREDICTORS OF SURVIVAL IN ADOL
Page 493 and 494:
abstracts small cell lung cancer an
Page 495 and 496:
emaining receiving either CAV or to
Page 497 and 498:
1533P EXPRESSION OF WILM⍰TUMOUR G
Page 499 and 500:
more than 3 months after first line
Page 501 and 502:
lower recurrence rate of NE. Pegfil
Page 503 and 504:
egimens (HR = 2.5, p < 0.001). Phys
Page 505 and 506:
1561P PREDICTIVE DIAGNOSTICS FOR RE
Page 507 and 508:
Methods: A prospective multicentre
Page 509 and 510:
Table: 1574P Pharmacokinetic parame
Page 511 and 512:
Novartis and unrestricted research
Page 513 and 514:
studies have shown that chemotherap
Page 515 and 516:
(Grade 1) and moderate to severe (G
Page 517 and 518:
declined to relatively lower level
Page 519 and 520:
1609P PHYSICAL ACTIVITY (PA) AND PH
Page 521 and 522:
patients were admitted to the oncol
Page 523 and 524:
Dicarbamin 100 mg/day on day 5 befo
Page 525 and 526:
Results: Anemia was detected in 83.
Page 527 and 528:
important to carry out randomized s
Page 529 and 530:
abstracts translational research 16
Page 531 and 532:
expression. Then, we analyzed PB sa
Page 533 and 534:
Table: 1657P TH BV + TH HR (95% CI)
Page 535 and 536:
BRAF mutations. Circulating free DN
Page 537 and 538:
1671P PHASE I CLINICAL TRIAL OF CAN
Page 539 and 540:
1678P PREDICTIVE VALUE OF TWO PHENO
Page 541 and 542:
theorized that the PI3K/AKT pathway
Page 543 and 544:
Material and methods: 101 patients
Page 545 and 546:
overexpressing and 232 had triple n
Page 547 and 548:
author index author index A Aamdal
Page 549 and 550:
author index Badran A. ix288 (874)
Page 551 and 552:
author index Bösmüller H. ix209 (
Page 553 and 554:
author index Chen A. ix319 (966O) C
Page 555 and 556:
author index De Droogh E. ix452 (13
Page 557 and 558:
author index Esposito G. ix209 (618
Page 559 and 560:
author index Geiges G. ix306 (930P)
Page 561 and 562:
author index Hartono S. ix70 (155P)
Page 563 and 564:
author index Iwasaki H. ix542 (1694
Page 565 and 566:
author index Kodaira M. ix90 (228P)
Page 567 and 568:
author index Lichtensztejn D. ix350
Page 569 and 570:
author index Martinez A. ix496 (153
Page 571 and 572:
author index Morishita N. ix432 (13
Page 573 and 574:
author index Okamoto N. ix432 (1320
Page 575 and 576:
author index Piau S. ix456 (1401P)
Page 577 and 578:
author index Rodríguez Rodríguez
Page 579 and 580:
author index Scoggins C.R. ix371 (1
Page 581 and 582:
author index Stern L. ix272 (823P)
Page 583 and 584:
author index Trypaki M. ix429 (1308
Page 585 and 586:
author index Whitmore J.B. ix310 (9
Page 587 and 588:
subject index subject index A AAV-H
Page 589 and 590:
subject index ix115 (316TiP), ix116
Page 591 and 592:
subject index diffuse large B-cell
Page 593 and 594:
subject index (1033P), ix340 (1036P
Page 595 and 596:
subject index medical information,
Page 597 and 598:
subject index (612P), ix214 (633),
Page 599 and 600:
subject index RCC, ix274 (830P) re-
Page 601 and 602:
subject index TR-FRET, ix84 (206P)
Page 603 and 604:
drug index drug index 1248P, 1250P,
Page 605 and 606:
translational research index transl
Page 607 and 608:
Page 609:
show all

Download the ESMO 2012 Abstract Book - Oxford Journals

Create successful ePaper yourself

Delete template?

Save as template?